Topical antiviral formulations

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9283182
APP PUB NO 20110120475A1
SERIAL NO

12890337

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE CONRAD PROGRAM OF THE EASTERN VIRGINIA MEDICAL SCHOOL ("CONRAD")1911 NORTH FORT MYER DRIVE SUITE 900 ARLINGTON VA 22209
INTERNATIONAL PARTNERSHIP FOR MICROBICIDES INC ("IPM)1010 WAYNE AVENUE SUITE 1450 SILVER SPRING MD 20910

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dahl, Terrence C Sunnyvale, US 25 383

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 15, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00